Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics.
Encellin has raised $9.9M in total funding. The most recent round was Series A. The last funding was announced in December 2023.
Encellin's investors include Y Combinator, Khosla Ventures, Endurance28, Sand Hill Angels, Formic Ventures.
Encellin is headquartered in San Francisco, United States.
Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics.
Encellin is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Encellin — Funding & Investors." VCBacked, December 13, 2023, https://www.vcbacked.co/company/encellin. Accessed August 23, 2026.
VCBacked. (2023). Encellin — Funding & Investors. Retrieved August 23, 2026, from https://www.vcbacked.co/company/encellin
{{cite web |title=Encellin — Funding & Investors |url=https://www.vcbacked.co/company/encellin |website=VCBacked |access-date=August 23, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated